Traumatic brain injury (TBI) causes multiple long-term defects including a loss of working memory that is frequently incapacitating. Administrations of mesenchymal stem/stromal cells (MSCs) previously produced beneficial effects in models of TBI as well as other disease models. In several models, the beneficial effects were explained by the MSCs being activated to express TSG-6, a multifunctional protein that modulates inflammation. In a mouse model of TBI, we found the initial mild phase of the inflammatory response persisted for at least 24 h and was followed by secondary severe response that peaked at 3 days. Intravenous human MSCs or TSG-6 during initial mild phase decreased neutrophil extravasation, expression of matrix metalloproteinase 9 by endothelial cells and neutrophils, and the subsequent blood brain barrier leakage in secondary phase. Administration of TSG-6 also decreased the lesion size at 2 weeks. Importantly, the acute administration of TSG-6 within 24 h of TBI was followed 6 to 10 weeks later by improvements in memory, depressive-like behavior and the number of newly born-neurons. The data suggested that acute administration of TSG-6 may be an effective therapy for decreasing some of the long-term consequences of TBI.
Introduction
Traumatic brain injury (TBI) is a leading cause of death and disability, particularly in young adults who fall victim to motor vehicle accidents, falls, sporting injuries, and physical assaults (Coronado et al., 2011) . Aside from the enormous personal burden, TBI generates substantial economic costs, estimated to be more than $55 billion dollars per year in the United States (Maas et al., 2008) . Despite advances in clinical care, a vast majority of the survivors of severe TBI are not able to live independently with a loss of working memory the most troubling symptom cited by patients (Myburgh et al., 2008) . TBI invokes a complex inflammatory response by the innate immune system mediated primarily through microglia and astrocytes but also involving cross talk with invading neutrophils, macrophages and T cells (Ransohoff and Brown, 2012) . The inflammatory response is both harmful and helpful in that it can cause excessive destruction of tissues, and it clears necrotic and apoptotic cells. A number of antiinflammatory agents have been tested in TBI but all have been disappointing. Glucocorticoids were used clinically to decrease brain edema but failed in a large clinical trial because of increased mortality (Edwards et al., 2005; Roberts et al., 2004) . Also, glucocorticoids were shown to aggravate retrograded memory deficits in a TBI model (Chen et al., 2009 ). Non-steroidal anti-inflammatory drugs produced mixed results in models for TBI with some reports indicating improvements (Kovesdi et al., 2012; Thau Zuchman et al., 2012) but others indicating deleterious effects such as worsened cognitive outcomes (Browne et al., 2006) . Strategies to reduce inflammation by targeting toll-like receptor (TLR) ligands, TLR receptors or pro-inflammatory cytokines have also proven ineffective (Rivest, 2011) .
Mesenchymal stem/stromal cells (MSCs) potentially offer a novel therapy for multiple central nervous system pathologies such as stroke, Parkinson's disease, experimental autoimmune encephalomyelitis, amyotrophic lateral sclerosis, and TBI (Chopp et al., 2008; Mahmood et al., 2004; Menge et al., 2012; Ohtaki et al., 2008; Parr et al., 2007; Pati et al., 2011; Prockop, 2007; Uccelli and Prockop, 2010; Zietlow et al., 2008) . However, their mode of action has not been clearly defined. We initially observed that administration of human MSCs limited injury to the brains of mice after transient global ischemia by modulating neuroinflammation (Ohtaki et al., 2008) . We also showed that MSCs suppressed endotoxin-induced glial activation in organotypic hippocampal slice cultures (Foraker et al., 2012) . More recently, we reported that some of the therapeutic effects of MSCs can be explained by
